Skip to main content

Table 2 Clinical outcomes of patients with community-acquired (CA), healthcare-associated (HCA), and nosocomial K. pneumoniae bacteremia

From: Clinical characteristics, antimicrobial resistance and capsular types of community-acquired, healthcare-associated, and nosocomial Klebsiella pneumoniae bacteremia

Variable CA (n = 70) HCA (n = 102) Nosocomial (n = 165) p value
CA vs. HCA HCA vs. Nosocomial CA vs. Nosocomial
Appropriate empirical antimicrobial therapy 68 (97.1) 91 (89.2) 133 (80.6) 0.077 0.063 < 0.001
Appropriate definite antimicrobial therapy 65 (92.9) 93 (91.2) 138 (83.6) 0.692 0.080 0.059
Length of stay after bacteremia, median (IQR), days 14.0 (8.0–23.8) 16.0 (9.8–28.0) 17.0 (7.0–30.5) 0.191 0.685 0.406
Septic shock when bacteremia 15 (21.4) 35 (34.3) 58 (35.2) 0.068 0.889 0.038
Respiratory failure requiring mechanical ventilation 6 (8.6) 14 (13.7) 9 (5.5) 0.300 0.019 0.371
Mortality
 In-hospital mortality 12 (17.1) 25 (24.5) 67 (40.6) 0.248 0.007 < 0.001
 Crude 28-day mortality 10 (14.3) 18 (17.6) 51 (30.9) 0.557 0.016 0.008
  1. IQR interquartile range, ICU intensive care unit
  2. Data are presented as number (%) of patients, unless stated otherwise